Amgen’s Rare Disease Portfolio Grows With Second Approved Uplizna Indication

Generalized Myasthenia Gravis Could Be Third

 
• By Mandy Jackson
  
Uplizna's approval in IgG4-RD adds to the rare disease foundation Amgen built with its Horizon acquisition (Shutterstock)

More from Strategy

More from Scrip